DNLI supply chain intelligence for Denali Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Denali Therapeutics Inc. (DNLI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ROYALTY-PHARMA-INVESTMENTS-2023-ICAV | ROYALTY-PHARMA-INVESTMENTS-2023-ICAV | 92% | The Company accounts for the synthetic royalty funding agreement with Royalty Pharma Investments 2023 ICAV ("Royalty Pharma") pursuant to which Royalty Pharma agreed to provide up to $ 275.0 million … |
| TKPHF | Takeda Pharmaceutical Company Limited | 92% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from DNLI graph: On April 3, 2026, Denali Therapeutics Inc. received written notice from Takeda Pharmaceutical Company Limited ('Take… |
| TKPHF | Takeda Pharmaceutical Company Limited | 92% | On April 3, 2026, Denali Therapeutics Inc. received written notice from Takeda Pharmaceutical Company Limited ('Takeda') of its decision to terminate the Collaboration Agreement (the 'Agreement'), da… |
| RPRX | Royalty Pharma plc | 90% | Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December … |
| RPRX | Royalty Pharma plc | 90% | The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December 4, 2025 related to the synthetic royalty funding agreement between the Company and… |
| BIOGEN | BIOGEN | 80% | We have numerous arrangements with biopharmaceutical companies, technology companies, academic institutions, foundations, and patient-focused data companies. Notable active arrangements include those… |
| TAKEDA | TAKEDA | 80% | We have numerous arrangements with biopharmaceutical companies, technology companies, academic institutions, foundations, and patient-focused data companies. Notable active arrangements include those… |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT grap… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| SNYNF | Sanofi | 72% | entual commercialization of one or more of our product candidates. We expect to continue to incur significant expenses and operating losses as we advance our current clinical stage programs through h… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: entual commercialization of one or more of our product candidates. We expect to continue to incur significant expens… |
| SANOFI | SANOFI | 70% | We hold significant development and commercialization rights to all of our CNS programs, including the programs which are subject to our collaboration agreements with Biogen and Takeda, where we shar… |
| ALEC | Alector, Inc. | 62% | Reciprocal relationship from ALEC graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from ALEC graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from ALEC g… |
| AZI | Autozi Internet Technology (Global) Ltd. | 62% | Reciprocal relationship from AZI graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from AZI graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from AZI grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED | TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED | 90% | The opt-in by Takeda on the PTV:PGRN and ATV:TREM2 programs represented two new contracts with a customer for accounting purposes |
| TKPHF | Takeda Pharmaceutical Company Limited | 90% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from TKPH… |
| BIOGEN | BIOGEN | 85% | we fund our operations primarily with the proceeds from the sale of common stock and payments received from our collaboration partners, including those received under agreements with Takeda, Sanofi, … |
| SANOFI | SANOFI | 85% | we fund our operations primarily with the proceeds from the sale of common stock and payments received from our collaboration partners, including those received under agreements with Takeda, Sanofi, … |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obta… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from DNLI graph: pricing, availability, quality, and… |
| MYGN | Myriad Genetics, Inc. | 72% | pricing, availability, quality, and delivery schedules. Unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements, including recently imposed tarif… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX g… |
| RPRX | Royalty Pharma plc | 72% | Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX g… |
| SNYNF | Sanofi | 72% | V:PGRN Technology License performance obligation delivered in the collaboration agreement. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literatur… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYN… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | s previously delivered. The Alzheimer’s Disease Services and the Retained Activities were expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, reven… |
| CATALYST-PHARMS-INC | CATALYST-PHARMS-INC | 62% | kruptcy or insolvency proceedings. If Genentech terminates the agreement for our material breach, bankruptcy or insolvency after we have made a milestone payment to Genentech, then we are obligated t… |
| CO-LLC | CO-LLC | 62% | . In February 2025, we established a registered “at-the-market” facility for the potential future sale of up to $400.0 million of shares of common stock from time to time by entering into an equity d… |
| F-STAR-BIOTECHNOLOGY-LIMITED | F-STAR-BIOTECHNOLOGY-LIMITED | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| F-STAR-GAMMA-LIMITED | F-STAR-GAMMA-LIMITED | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| F-STAR-LTD | F-STAR-LTD | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | . In February 2025, we established a registered “at-the-market” facility for the potential future sale of up to $400.0 million of shares of common stock from time to time by entering into an equity d… |
| LONZA-SALES-AG | LONZA-SALES-AG | 62% | not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not kn… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DNLI-DEBT | Debt stack $40.0M | 90% | Market cache reports total debt of $40.0M. |
| DNLI-DEBT-9105 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DNLI-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 272 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AZI | Autozi Internet Technology (Global) Ltd. | 100.00 | 1 | ['supplier'] |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |